
KMDA: Is Kamada Ltd. Halal?
Kamada Ltd.
$8.23
-0.72%
Market Cap: 474.8M
Compliance Status
Halal
Screened on Sep 1, 2026 · AAOIFI Standard 21
Good
Is Kamada Ltd. (KMDA) halal? Halal. Based on AAOIFI screening, Kamada Ltd. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 79/100 (Grade: B+).
Quote this verdict
HalalScreener rates Kamada Ltd. (KMDA) Halal, 79/100, grade B+ under AAOIFI Standard 21, screened Sep 1, 2026. Source: https://halalscreener.app/en/stock/KMDA
Business activity
What the company sells is permissible.
Company debt
Well clear of the limitHow much the company borrows, compared to its total value. AAOIFI allows up to 30%.
What this means for you
You can own KMDA
It passes both the business activity and financial ratio screens under AAOIFI Standard 21.
Purification amount is Pro
We have screened KMDA's prohibited income, but the exact share you would need to purify is part of Pro.
About Kamada Ltd.
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic
Shariah Compliance Status
Compliance History
Halal, unchanged since May 2026.
No status changes recorded since we began tracking.
Tracked since May 2026. Updates automatically on each re-screen.
More Healthcare Stocks
Track KMDA and 6,200+ stocks with AI insights
Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.
Frequently Asked Questions
Is Kamada Ltd. (KMDA) halal to invest in?
Why did Kamada Ltd. get a B+ compliance rating?
What could change Kamada Ltd.'s Shariah verdict?
How often is Kamada Ltd. re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.